Terms: = Breast cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Diagnosis
88 results:
1. Doses to the right coronary artery and the left anterior descending coronary artery and death from ischemic heart disease after breast cancer radiotherapy: a case-control study in a population-based cohort.
Perman M; Johansson KA; Holmberg E; Karlsson P
Acta Oncol; 2024 Apr; 63():240-247. PubMed ID: 38682458
[TBL] [Abstract] [Full Text] [Related]
2. [A Case Report of Metastatic breast cancer with Peritoneal Metastasis and Massive Ascites Responding to cdk4/6 Inhibitor(Palbociclib)].
Yao S; Goi T; Takahashi M; Kono H; Yokoi S; Maeda H
Gan To Kagaku Ryoho; 2024 Feb; 51(2):214-216. PubMed ID: 38449417
[TBL] [Abstract] [Full Text] [Related]
3. Combination therapy application of Abemaciclib with Doxorubicin in triple negative breast cancer cell line MDA-MB-231.
Eralp TN; Sevinc A; Mansuroglu B
Cell Mol Biol (Noisy-le-grand); 2024 Feb; 70(2):169-177. PubMed ID: 38430025
[TBL] [Abstract] [Full Text] [Related]
4. [Recurrent breast cancer with Bone Metastasis Effectively Treated with Abemaciclib plus Endocrine Therapy-A Case Report].
Adachi K; Nagae J; Kubota H; Suzuki S; Hirano T; Sakurai K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1845-1847. PubMed ID: 38303227
[TBL] [Abstract] [Full Text] [Related]
5. [Bone Marrow Carcinomatosis with Disseminated Intravascular Coagulation in a breast cancer Patient Treated with Chemotherapy and cdk4/6 Inhibitor].
Kume S; Makino T; Goto A; Onodera Y; Kudo S
Gan To Kagaku Ryoho; 2023 Dec; 50(12):1331-1333. PubMed ID: 38247075
[TBL] [Abstract] [Full Text] [Related]
6. Exploring adherence in patients with advanced breast cancer: focus on cdk4/6 inhibitors.
Baković M; Bago M; Benić L; Krajinović M; Silovski T; Plavetić ND; Turković L; Sertić M; Hadžiabdić MO
Acta Pharm; 2023 Dec; 73(4):633-654. PubMed ID: 38147481
[TBL] [Abstract] [Full Text] [Related]
7. IGF2BP2 Drives Cell Cycle Progression in Triple-Negative breast cancer by Recruiting EIF4A1 to Promote the m6A-Modified CDK6 Translation Initiation Process.
Xia T; Dai XY; Sang MY; Zhang X; Xu F; Wu J; Shi L; Wei JF; Ding Q
Adv Sci (Weinh); 2024 Jan; 11(1):e2305142. PubMed ID: 37983610
[TBL] [Abstract] [Full Text] [Related]
8. More Than Meets the Eye: A Case of breast cancer Switching from Being Luminal-Androgen-Receptor-Positive to Being Hormone-Receptor-Positive.
Martorana F; Di Grazia G; Rosano GN; Vecchio GM; Conti C; Nucera S; Magro G; Vigneri P
Medicina (Kaunas); 2023 Oct; 59(10):. PubMed ID: 37893593
[TBL] [Abstract] [Full Text] [Related]
9. [Expert consensus on endocrine therapy of breast cancer (2023 edition)].
Zhang SH; Wang XJ; Jiang ZF
Zhonghua Yi Xue Za Zhi; 2023 Oct; 103(38):2993-3001. PubMed ID: 37813650
[TBL] [Abstract] [Full Text] [Related]
10. Utility of psychotherapy assessed with Kessler scale in a population of cancer patients undergoing systemic oncological treatment: a mono-institutional experience.
Vitale P; Bocchino I; De Falco V; Auletta G; Di Giovanni I; Bocchetti M; Auriemma A; Conchiglia R; Addeo R
Chin Clin Oncol; 2023 Aug; 12(4):35. PubMed ID: 37699600
[TBL] [Abstract] [Full Text] [Related]
11. Sarcoma care in the era of precision medicine.
Wallander K; Öfverholm I; Boye K; Tsagkozis P; Papakonstantinou A; Lin Y; Haglund de Flon F
J Intern Med; 2023 Dec; 294(6):690-707. PubMed ID: 37643281
[TBL] [Abstract] [Full Text] [Related]
12. Real-world outcomes of patients with metastatic endocrine-responsive breast cancer receiving palbociclib-based combinations.
Moser SS; Mazursky OF; Shalev H; Apter L; Chodick G; Siegelmann-Danieli N
Future Oncol; 2023 Jul; 19(21):1473-1483. PubMed ID: 37529919
[TBL] [Abstract] [Full Text] [Related]
13. Radiation Pneumonitis, Really? A Case of Pulmonary Toxicity from cdk4/6 Inhibitor.
Hunt A; Haque W; Pino R; Farach A; Butler EB; Teh BS
Anticancer Res; 2023 Aug; 43(8):3539-3542. PubMed ID: 37500128
[TBL] [Abstract] [Full Text] [Related]
14. An Overview of the Roles of cdk4/6 Inhibitors in Metastatic breast cancer Elderly Patients.
Pacilio C; Rosati G; Crispo A; Bimonte S; DI Rella F; Nuzzo F; DE Laurentiis M
In Vivo; 2023; 37(4):1445-1449. PubMed ID: 37369460
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic breast cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors.
Rao X; Chen Y; Beyrer J; Nash Smyth E; Morato Guimaraes C; Litchfield LM; Bowman L; Lawrence GW; Aggarwal A; Andre F
Clin Cancer Res; 2023 Sep; 29(17):3372-3383. PubMed ID: 37289194
[TBL] [Abstract] [Full Text] [Related]
16. Regulation of the Cell Cycle by ncRNAs Affects the Efficiency of cdk4/6 Inhibition.
Hu Q; Huang T
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240281
[TBL] [Abstract] [Full Text] [Related]
17. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic breast cancer.
Cejuela M; Gil-Torralvo A; Castilla MÁ; Domínguez-Cejudo MÁ; Falcón A; Benavent M; Molina-Pinelo S; Ruiz-Borrego M; Salvador Bofill J
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239834
[TBL] [Abstract] [Full Text] [Related]
18. Survival Outcomes in Patients With Hormone Receptor-Positive Metastatic breast cancer With Low or No ERBB2 Expression Treated With Targeted Therapies Plus Endocrine Therapy.
Mouabbi JA; Singareeka Raghavendra A; Bassett RL; Hassan A; Tripathy D; Layman RM
JAMA Netw Open; 2023 May; 6(5):e2313017. PubMed ID: 37166793
[TBL] [Abstract] [Full Text] [Related]
19. The breast cancer Proteome and Precision Oncology.
Lei JT; Jaehnig EJ; Smith H; Holt MV; Li X; Anurag M; Ellis MJ; Mills GB; Zhang B; Labrie M
Cold Spring Harb Perspect Med; 2023 Oct; 13(10):. PubMed ID: 37137501
[TBL] [Abstract] [Full Text] [Related]
20. Unilateral breast enlargement in males during adolescence (10-19 years): Review of current literature and personal experience.
De Sanctis V; Soliman AT; Tzoulis P; Daar S; Di Maio S; Kattamis C
Acta Biomed; 2023 Apr; 94(2):e2023004. PubMed ID: 37092615
[TBL] [Abstract] [Full Text] [Related]
[Next]
